Articles

Researchers reported results of in-depth molecular profiling performed on samples from African Americans and European Americans with multiple myeloma enrolled in the longitudinal CoMMpass study. Read More ›

This study assessed factors that influenced the use of 3-drug combination therapy as a second-line treatment choice in patients with relapsed/refractory multiple myeloma (RRMM) who were managed in routine care. Read More ›

In this study, the clinical value of minimal residual disease (MRD) status in achieving prolonged remissions was assessed in patients with multiple myeloma (MM) who had achieved at least very good partial response or complete response at 4 to 8 months and 12 to 24 months, or long-term relapse-free survivors (>6 years). Read More ›

Beth Faiman argues that patient support services are integral in her role as a nurse because they aid in getting patients the treatments they need, promote adherence, and provide patient education. Read More ›

Researchers presented updated results of the randomized phase 3 ELOQUENT-2 study that evaluated the anti-SLAM7 monoclonal antibody elotuzumab plus lenalidomide/dexamethasone versus lenalidomide/dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM). Read More ›

This study analyzed data from the longitudinal CoMMpass trial led by the Multiple Myeloma Research Foundation to determine the degree to which the International Staging System (ISS) stage was associated with disease and symptom burden in patients with newly diagnosed multiple myeloma (MM). Read More ›

Researchers reported long-term follow-up results of the HOVON-65/GMMG-HD4 trial that evaluated survival outcomes with bortezomib-based induction and maintenance regimens followed by high-dose melphalan and autologous stem-cell transplantation in transplant-eligible patients with newly diagnosed multiple myeloma (MM) compared with the standard regimen. The impact of the bortezomib-based regimen on survival in the high-risk cytogenetic and renally impaired subset of patients was also reported. Read More ›

To further optimize therapy, this study identified subgroups that benefited least from bortezomib/melphalan/prednisone followed by lenalidomide/dexamethasone regimen in newly diagnosed patients aged 65 to 80 years with multiple myeloma (MM) included in the GEM2010 trial. Read More ›

Ali McBride provides some ideas to promoting oral adherence. Read More ›

R. Donald Harvey offers suggestions for what might help with greater medication adherence. Read More ›